DiaMedica Therapeutics, a Phase 2 biotech targeting acute ischemic stroke and chronic kidney disease, filed on Friday with the SEC to raise up to $15 million in an initial public offering. DiaMedica is currently listed on both the OTCQB marketplace and the Toronto Stock Exchange.
The Minneapolis, MN-based company was founded in 2000 and plans to list on the Nasdaq under the symbol DMAC. DiaMedica Therapeutics filed confidentially on November 1, 2018. Craig-Hallum Capital Group is the sole bookrunner on the deal. No pricing terms were disclosed.
